Author:
RAGNI M. V.,FOGARTY P. J.,JOSEPHSON N. C.,NEFF A. T.,RAFFINI L. J.,KESSLER C. M.
Subject
Genetics(clinical),Hematology,General Medicine
Reference22 articles.
1. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia;Manco-Johnson;N Engl J Med,2007
2. National Hemophilia Foundation Medical and Scientific Advisory Council (MASAC Recommendation Concerning Prophylaxis: Regular Administration of Clotting Factor Concentrate to Prevent Bleeding (#179) http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007
3. Central venous catheter infection in hemophiliacs undergoing prophylaxis or immune tolerance;Ragni;Haemophilia,1997
4. Tissue plasminogen activator to prevent central venous access device infection: A systematic review of CVAD thrombosis, infection, and thromboprophylaxis;Ragni;Haemophilia,2008
5. Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia;Jeng;Haemophilia,2009
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献